Drug Research
BioMotiv and Atomwise Sign AI Partnership to Transform Therapeutic...
BioMotiv, a mission-driven pharma company part of The Harrington Project for discovery and development, and Atomwise, the leader in using artificial intelligence (AI) for small...
Drug Research
Astellas Announces Construction of New Manufacturing Facility for Active...
The new manufacturing facility is designed to have advanced features based on the efficiency of the existing facilities and requires approximately JPY10bn ($90m) in construction...
Drug Research
CytoviaTherapeutics and the University of California enter into a...
CytoviaTherapeutics,a biopharmaceutical company, and the University of California,San Francisco(UCSF) announced that they have entered a 3-year research partnership to develop novel precision gene editing to...
Drug Research
Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11...
Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced the acquisition of worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to...
Drug Research
BI Vaccines Announces Second Pivotal Phase 3 Study of...
VBI Vaccines Inc. (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, reported top-line data from CONSTANT, the second pivotal Phase 3...
Drug Research
Generation Bio Announces $110 Million Series C Financing to...
Generation Bio, a company leading a new generation of gene therapy, announced the closing of a $110 million Series C financing. Proceeds will be used...
Drug Research
Bayer and Exscientia collaborate to leverage the potential of...
Bayer and Exscientia Ltd., a UK-based Artificial Intelligence (AI)-driven drug discovery company, have entered into a three-year, multi-target collaboration. The partners will work on early...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.